Glenmark gets USFDA nod for generic skin ointment

The Mumbai-based firm's product is the generic version of Perrigo New York Inc's Desonide Ointment

Last Updated : Sep 19 2017 | 4:23 PM IST

Glenmark Pharmaceuticals today said it has received approval from the US health regulator to market Desonide Ointment, used to treat skin problems, in the American market.

Glenmark Pharmaceuticals Inc, a subsidiary of the company, has received final approval from the US Food and Drug Administration (US FDA) for Desonide ointment, the company said in a statement.

The Mumbai-based company's product is the generic version of Perrigo New York Inc's Desonide Ointment.

Glenmark Pharma gets USFDA nod for generic skin ointment

Glenmark Pharma gets USFDA approval for skin cream generic

US FDA approves Glenmark Pharma's drug for overactive bladder

After disappointing Q4, Glenmark gives a guidance of 15% revenue growth

Lupin receives USFDA approval for generic anti-inflammatory ointment

As per the latest IMS Health sales data, the product had annual sales of around USD 23.4 million.

Glenmark's current portfolio consists of 124 products authorised for distribution in the US marketplace and 62 ANDAs pending approval with the US FDA.

Shares of the company were at Rs 620 apiece at BSE, up 2.15 per cent from the previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Already subscribed? Log in

Subscribe to read the full story →

^*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

In-depth market analysis & insights with access to The Smart Investor

Ad-free Reading

Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

Access Business Standard across devices — mobile, tablet, or PC, via web or app